Shares of Opexa Therapeutics Inc (NASDAQ:OPXA) are up considerably this afternoon following a presentation in Boston, Ma. earlier in the month. While the gains may not be all directly attributed to this presentation, shares are coming off of quite a beating over the last six month, and have performed even worse over the last couple of years, trading at over $17 for a brief period in March of last year.
The company’s main product, Tcelna, which is a personalized T-cell immunotherapy currently in Phase 2b development for Fast Track-designated secondary progressive multiple sclerosis, will likely see trial results later next year. While these results could go either way, the fact that the company is burning approximately $1 million in cash every month may have some shareholders a bit nervous. The company currently has approximately $16 million in cash on their balance sheet.The stock is up 13.33% or $0.46 after the positive news, hitting $3.91 per share. About 5.12M shares traded hands or 3148.38% up from the average. OPXA has risen 702.33% since April 22, 2015 and is uptrending. It has outperformed by 703.34% the S&P500.
Out of 2 analysts covering Opexa Therapeutics (NASDAQ:OPXA), 2 rate it “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Opexa Therapeutics was the topic in 2 analyst reports since September 28, 2015 according to StockzIntelligence Inc. Chardan Capital Markets initiated the stock on November 4 with “Buy” rating.
The institutional sentiment increased to 1.43 in Q2 2015. Its up 0.86, from 0.57 in 2015Q1. The ratio improved, as 6 funds sold all Opexa Therapeutics Inc shares owned while 1 reduced positions. 5 funds bought stakes while 5 increased positions. They now own 2.64 million shares or 38.34% more from 1.91 million shares in 2015Q1.
Bank Of America Corp De holds 0% of its portfolio in Opexa Therapeutics Inc for 1,862 shares. California Public Employees Retirement System owns 532,100 shares or 0% of their US portfolio. Moreover, Citadel Advisors Llc has 0% invested in the company for 153,885 shares. The New York-based Citigroup Inc has invested 0% in the stock. Commonwealth Equity Services Inc, a Massachusetts-based fund reported 10,000 shares.
Opexa Therapeutics, Inc. is a biopharmaceutical firm developing a personalized immunotherapy with the potential to treat various illnesses, including multiple sclerosis (MS), as well as other autoimmune diseases, such as neuromyelitis optica (NMO). The company has a market cap of $23.49 million. These therapies are based on the Company’s T-cell technology. It currently has negative earnings. It is engaged in the field of Precision Immunotherapy.